Biotech Values

[genisi]

If the idea of direct infusion of HDL turns out to have merit, I would expect a non-plasma-derived product to be more marketable as long as the production cost is not excessive.

I believe Esperion were thinking the same and were (perhaps still are) looking for ways to improve manufacturing and reduce cost of their recombinant ApoA-I Milano/phospholipid complex. http://www.esperion.com/modules/xnews/article.php?storyid=4
I guess MDCO is in the same boat. No idea what expression system they use/d.
Another player with a recombinant ApoA-I:

http://www.cerenis.com/pipeline_cer001.asp